Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H48N2O8S |
Molecular Weight | 572.754 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O
InChI
InChIKey=URJQSMIFSMHWSP-VVHBOOHCSA-N
InChI=1S/C28H48N2O8S/c1-16(4-7-24(34)30-15-25(35)29-10-11-39(36,37)38)19-5-6-20-26-21(14-23(33)28(19,20)3)27(2)9-8-18(31)12-17(27)13-22(26)32/h16-23,26,31-33H,4-15H2,1-3H3,(H,29,35)(H,30,34)(H,36,37,38)/t16-,17+,18-,19-,20+,21+,22-,23+,26+,27+,28-/m1/s1
Molecular Formula | C28H48N2O8S |
Molecular Weight | 572.754 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 11 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sodium tauroglycocholate presents in ENZAR FORTE tablet, together with enzymes: amylase, lipase and protease. ENZAR FORTE is indicated for the treatment of the following digestive symptoms: indigestion/dyspepsia; flatulence; bloating; fullness after eating; heartburn; anorexia; hepatic and pancreatic insufficiency; post-operative digestive upsets and convalescence. Discomfort, flatulence, and abdominal colic may result when the bodies own pancreatic enzymes cannot cope with excessive quantities of food consumed. In such cases, the enzymes present in ENZAR FORTE enhance the digestive processes in a natural way, thereby reducing the amount of undigested food available for fermentation & putrefaction. Amylase enzyme helps in the digestion of starch, lipase is involved in the digestion of lipids, and protease is required for digestion of proteins. The advantage of bile salt i.e. sodium tauroglycocholate for improving absorption of fat & fat-soluble vitamins.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Biliary acid transporting system Sources: https://www.ncbi.nlm.nih.gov/pubmed/8377117 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ENZAR FORTE Approved UseUnknown |
|||
Palliative | ENZAR FORTE Approved UseUnknown |
|||
Palliative | ENZAR FORTE Approved UseUnknown |
|||
Palliative | ENZAR FORTE Approved UseUnknown |
|||
Palliative | ENZAR FORTE Approved UseUnknown |
|||
Palliative | ENZAR FORTE Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Each enteric-coated tablet contains: Amylase activity -15,000 USP units; Lipase activity - 4,000 USP units; Protease activity - 15,000 USP units of (derived from Pancreatin USP) Sodium tauroglycocholate BPC – 65mg (with sugar coating containing essential carminative oils).
As a digestive enzyme: 1 tablet to be sucked (not chewed) for few seconds and then swallowed with every meal. In pancreatic insufficiency: Up to 2 tablets 2-3 times a day can also be given. But dosage is individualized depending on patient’s pancreatic function.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:16:13 GMT 2023
by
admin
on
Sat Dec 16 14:16:13 GMT 2023
|
Record UNII |
VV181JY3L5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
26198-66-3
Created by
admin on Sat Dec 16 14:16:13 GMT 2023 , Edited by admin on Sat Dec 16 14:16:13 GMT 2023
|
PRIMARY | |||
|
VV181JY3L5
Created by
admin on Sat Dec 16 14:16:13 GMT 2023 , Edited by admin on Sat Dec 16 14:16:13 GMT 2023
|
PRIMARY | |||
|
119420
Created by
admin on Sat Dec 16 14:16:13 GMT 2023 , Edited by admin on Sat Dec 16 14:16:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |